Cholinesterases: New roles in brain function and in Alzheimer's disease

Neurochemical Research

Volumn 28, Issue 3-4, 2003, Pages 515-522

  Giacobini, Ezio ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Alzheimer's disease; APP (amyloid precursor protein), amyloid; Butyrylcholinesterase; Cholinergic stabilization; Cholinesterase inhibitors

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; BRAIN PERFUSION; CEREBROSPINAL FLUID; CHOLINERGIC ACTIVITY; COGNITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ASSAY; ENZYME INHIBITION; EXTRACELLULAR SPACE; HYDROLYSIS; KINETICS; NONHUMAN; PRIORITY JOURNAL; RAT; RELAPSE;

ALZHEIMER DISEASE; ANIMALS; BRAIN; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; HUMANS; REFERENCE VALUES;

ANIMALIA; MAMMALIA;

EID: 0037375876     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022869222652     Document Type: Article

References (42)

1. Farlow, M. 2000. New approaches in assessing delay of progression of AD. Symp. Pivotal Res. World Alzheimer Congress, Washington, D. C. Abstr.: 10-11.
2. Anand, R., Hartman, R., and Messina, J. 1998. Long-term treatment with rivastigmine continue to provide benefits for up to one year. Fifth International Geneva/Springfield Symposium on Advances in Alzheimer Therapy Geneva, Abstr.:18.
3. Nitsch, R. M. 1992. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258:304-307.
4. Mori, F., Lai, C. C., Fusi, F., and Giacobini, E. 1995. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neurol. Rep. 6:633-636.
5. Racchi, M., Schmidt, B., and Koenig, G. 1999. Treatment with metrifonate promotes soluble amyloid precursor protein release from SH-SY5Y neuroblastoma cells. Alz. Dis. Assoc. Dis 27: 679-688.
6. Pakaski, M., Rakonczay, Z., and Kasa, P. 2001. Reversible or irreversible cholinesterase inhibitors cause changes in neuronal amyloid percursor processing and protein kinase C level in vitro. Neurochem. Int. 38:219-226.
7. Giacobini, E. 1996. Cholinesterase inhibitors do more than inhibit cholinesterase. Pages 187-204, in Becker, R. and Giacobini, E. (eds.), Alzheimer Disease: From Molecular Biology to Therapy, Birkhäuser, Boston.
8. Nitsch, R. 2000. Muscarinic agonists reduce CSF levels of amyloid beta-peptides in patients with Alzheimer's disease. XVth International Symposium of Medicinal Chemistry, Bologna, Abstr. M1-41:52.
9. Lahiri, D. K., Farlow, M. R., Hintz, N., Utsuki, T., and Greig, N. H. 2000. Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease. Acta Neurol. Scand. (Suppl.) 176:60-67.
10. Svensson, A. L. and Giacobini, E. 2000. Cholinesterase inhibitors do more than inhibit cholinesterase. Pages 227-235, in Giacobini, E. (ed.), Cholinesterases and Cholinesterase Inhibitors, Martin Dunitz.
11. Shaw, K., Utsuki, T., Rogers, J., Qiang-Sheng, Y., Sambamurti, K., and Brossi, A. 2001. Phenserine regulates translation of β-amyloid precursor protein mRNA by a putative interleukin1 responsive element, a target for drug development. Proc. Natl. Acad. Sci. USA. 19:7605-7610.
12. Lahiri, D. K., Farlow, M. R., Ge, Y. W., Sambamurti, K., Utsuki, T., Ingram, D. K., and Greig, N. H. 2002. Phenserine: A new generation of cholinesterase inhibitors with amyloid-modifying properties. Seventh International Geneva Springfield Symposium 2002. Abstr.:80.
13. Inestrosa, N. C., Alvarez, A., Reyes, A., and De Ferrari, G. V. 2000. Acetylcholinesterase-amyloid-peptide interaction and Wnt signaling involvment in A-beta neurotoxicity. Acta Neurol. Scand. (Suppl.) 176:53-59.
14. Inestrosa, N. C. and De Ferrari, G. V. Cholinesterase inhibitors with anti-amyloid properties. 7th International Geneva Springfield Symposium 2002. Abstr.:74.
15. Geula, C. and Mesulam, M. 1989. Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease. Brain Res. 498:185-189.
16. Alvarez, A. 1997. Acetylcholinesterase promotes the aggregation of amyloid ∃-peptide fragments by forming a complex with the growing fibrils. J. Mol. Biol. 272:348-361.
17. De Ferrari, G. V., Canales, M. A., Shin, I., Weiner, L. M., Silman, I., and Inestrosa, N. C. 2001. A structural motif of acetylcholinesterase that promotes amyloid ∃-peptide fibril formation. Biochemistry 40:10447-10457.
18. Giacobini, E. 2000. Cholinesterase inhibitors: From the calabar bean to Alzheimer therapy. Pages 181-122, in Giacobini, E. (ed.), Cholinesterase and Cholinesterase Inhibitors: From Molecular Biology to Therapy, Martin Dunitz, London.
19. Saez-Valero, J., Sberna, G., McLean, C. A., and Small, D. H. 1999. Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease. J. Neurochem. 72:1600- 1608.
20. Small, D. H., Sberna, G., and Li, Q. X. 1998. The ∃-amyloid protein influence acetylcholinesterase expression, assembly and glycosylation. Sixth International Conference on Alzheimer's Disease and Related Disorders, Amsterdam. Abstr.: 880.S.209.
21. Inestrosa, N., Alvarez, A., and Perez, C. A. 1996. Acetylcholinesterase accelerates assembly of amyloid-∃-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 16:881-891.
22. Rees, T., Hammond, P., Younkin, S., Soreq, H., and Brimijoin, S., 2002. Acetylcholinesterase facilitates amyloid deposition in a mouse model of Alzheimer's disease. Seventh International Symposium Cholinergic Mechanisms, St. Moritz Abstr.: 13.
23. Sberna, G., Saez-Valero, J., and Li, Q. X. 1998. Acetylcholinesterase is increased in the brains of transgenic mice expressing C-terminal fragment of the ∃-amyloid protein precursor of Alzheimer's disease. J. Neurochem. 71:723-731.
24. Haroutunian, V., Wallace, W. C., and Greig, N. 2000. Induction, secretion and pharmacological regulation of beta-APP in animal model systems. Sixth International Stockholm/Springfield Symposium Advances in Alzheimer Therapy. Abstr.:81.
25. Suh, Y. H., Chong, Y. H., and Kim, S. H. 1996. Molecular physiology, biochemistry and pharmacology of Alzheimer's amyloid precursor protein (APP). Ann. N. Y. Acad. Sci. 786:169-183.
26. Wallace, W. C., Bragin, V., and Robakis, N. K. 1991. Increased byosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis Meynert. Mol. Brain Res. 10:173-178.
27. Bernhardt, T. and Woelk, H. 2000. Metrifronate demonstrates sustained improvement in cognition and global functioning in a 12-month, double-blind placebo-controlled trial. Europ. Neurol. Soc. Meet. (Jerusalem), p. 36.
28. Winblad, B., Engedal, K., and Soininen, H. 1999. Donepezil enhances global function, cognition and activities of daily living compared with placebo one year. Twelfth Congretional ECNP, London Abstr.:30.
29. Raskind, M. A., Peskind, E. R., and Wessel, T. 2000. Galantamine in AD: A sixth month randomized, placebo-controlled trial with a 6-month extension. Neurology 54:2261-2268.
30. Silver, A. 1974. The biology of cholinesterases. Elsev. Publ USA, Agricultural Res. Council Institute: 426-447.
31. Giacobini, E. 2001. Selective inhibitors of butyrylcholinesterase: A valid alternative for therapy of Alzheimer's disease? Drug Aging 18:891-898.
32. Wright, C. I, Geula, C., and Mesulam, M. M. 1993. Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles and patterns of selective vulnerability. Ann. Neurol. 34:373-384.
33. Perry, E. K., Perry, R. H., Blessed G., and Tomlinson, B. E. 1978. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol. Appl. Neurobiol. 4:273-277.
34. Cuadra, G., Summers, K., and Giacobini, E. 1994. Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo. J. Pharmacol. Exper. Ther. 270:277-284.
35. Giacobini, E., Griffini, P. L., Maggi T., et al. 1996. The effect of MF8622, a selective butyrylcholinesterase inhibitor on cortical levels of acetylcholine. Soc. Neurosci. 22:203.
36. Cuadra, G. and Giacobini E. 1995. Coadministration of cholinesterase inhibitors and idazoxan: Effects of neurotransmitters in rat cortex in vivo. J. Pharm. Exp. Ther. 273:230-240.
37. Greig, N.H., Utsuki, T., Yu, Q., et al. 2001. Butyrylcholinesterase: A new therapeutic target in AD treatment? Alz. Insights 7,2, 1-4.
38. Mesulam, M. M., Guillozet, A., Shaw, P., Levey, A., Duysen, E. G., and Lockridge, O. 2002. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butylcholinesterase to hydrolyse acetylocholine. Neuroscience 110: 627-639.
39. Mesulam, M. M. and Geula, C. 1994. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann. Neurol. 36:722-727.
40. Darvesh, S., MacKnight, C., and Rockwood, K. 2001. Butyrylcholinesterase and cognitive function. Int. Psychogeriatr. 13: 461-464.
41. Costa, J., Anand, R., Cutler, N., et al. 1999. Correlation between cognitive effects and level of acetylcholinesterase inhibition in a trial of rivastigmine in Alzheimer's patients. Proc. Am. Psych. Assoc. Poster NR:561.
42. Giacobini, E., et al. 2002. Acetyl- and butyrylcholinesterase inhibition by rivastigmine in cerebrospinal fluid of patients with Alzheimer's disease correlates with cognitive benefit. J. Neural Transm. In press.